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Abstract: 
Unlike most neurodegenerative disorders, individuals at risk from Huntington’s 
disease can be identified prior to the onset of clinical signs of the disease by virtue of 
I being an autosomal dominant condition. This provides the hypothetical opportunity 
to delay disease onset and/or slow down the progression of the disease in the very 
early stages ahead of overt features of disease. To help prepare for therapeutic trials of 
disease modifying compounds extensive work has gone into: (1) finding ways of 
better predicting the onset of disease in pre-manifest HD gene carriers (PMGC), (2) 
defining the extent of non-motor features of HD and, (3) identifying robust and 
reliable tests by which to measure disease progression. In this short review we 
summarise some of the major findings in this area of clinical research. 
   
Introduction: 
Huntington’s disease (HD) is an inherited progressive neurodegenerative disorder, 
characterised genetically by an unstable CAG expansion in exon 1 of the huntingtin 
gene and clinically by a triad of motor, cognitive and psychiatric deficits. Unlike 
many neurodegenerative disorders, the genetic origin of HD means that the disease 
can be studied even before a clinical diagnosis has been made. At present, gene 
carriers are diagnosed with manifest disease upon the emergence of overt motor signs 
of disease however, research has shown that cognitive abnormalities (Stout et al., 
2011) and brain atrophy (Aylward et al., 1996) are both detectable many years prior to 
this point.  
 
Over the last 10 years great investment has gone into better understanding this 
prodromal stage of HD with the aim of (1) find ways of better predicting when pre-
manifest HD gene carriers (PMGC) will receive a clinical diagnosis, (2) to define the 
true extent of non-motor features of HD and, (3) to identify robust and reliable tests 
by which to measure disease progression. The field has been dominated by three 
large, multi-centre cohort studies: PREDICT-HD (Paulsen et al., 2008), the European 
Huntington’s Disease Network’s Registry study (Orth et al., 2010) and most recently 
TRACK-HD (Tabrizi et al., 2012, Tabrizi et al., 2011, Tabrizi et al., 2013a). All have 
taken a multimodal approach, using a combination of clinical measures, imaging and 
wet biomarkers, to interrogate the period immediately prior to and post clinical 
diagnosis in HD.   
 
Data from the TRACK-HD study (Tabrizi et al., 2012, Tabrizi et al., 2011, Tabrizi et 
al., 2013b) suggests that baseline apathy scores, the ability to recognise negative 
emotions and longitudinal changes in whole brain, grey-matter, white-matter and 
caudate volumes are all predictive of clinical diagnosis within a 3 year period in pre-
manifest HD gene carriers. Conversely however, PREDICT-HD (Paulsen et al., 2008) 
found that it was subtle increases on the UHDRS total motor score, changes in 
putamen volume or a reduction on the Stroop word reading score that were the best 
predictors of clinical diagnosis over a 5 year period. This lack of consistency is 
further replicated in the wider literature across many studies (for a review see (Dumas 
et al., 2013a)). Therefore, even when a similar methodology is used in a similar group 
of participants there still appears to be a fundamental heterogeneity within the pre-
manifest population that results in a lack of consensus about the measures which are 
the best predictors of clinical diagnosis.       
 
Although, it is worth noting that the point of clinical diagnosis is a subjective and 
somewhat arbitrary milestone especially in reference to both the neuropathology and 
neurobiology of HD. This may therefore, contribute to the variability seen between 
and within studies striving to find predictors of “disease onset”. In which case, going 
forward a more scientifically appropriate approach may be to treat disease progression 
as a continuous variable, beginning almost from birth.  
 
In this review we aim to summarise all the work on HD that has been published in the 
Journal of Neurology since 2012. Given that the aims discussed above, the studies 
concerned with predicting clinical diagnosis will be discussed first, followed by those 
which are applied across the disease spectrum and may therefore be useful for 
mapping disease progression.    
 
 1. Predicting clinical diagnosis in HD: 
Neuropathology 
Atrophy of the striatum has been reliably shown to occur a decade or more prior to the 
onset of motor features (Tabrizi et al., 2011, van den Bogaard et al.). There is also 
evidence of atrophy in many other brain structures including the frontal lobes, 
thalamus, globus pallidus and insula (Harris et al., 1999, Thieben et al., 2002, Paulsen 
et al., 2006, Aylward et al., 1998) with abnormalities in both white matter (Rosas et 
al., 2006, Dumas et al., 2012) and cortical grey matter (Tabrizi et al., 2011) during the 
pre-manifest stage.  However there is still discussion about the relationship these 
abnormalities have with the onset of disease and whether they could also have some 
developmental basis. A cross-sectional analysis of the imaging data collected as part 
of the TRACK-HD study has shown that the nucleus accumbens, the caudate nucleus, 
the pallidum and the putamen all display a progressive reduction in volume which is 
disproportionate to whole-brain atrophy and is apparent from very early pre-manifest 
stages (van den Bogaard et al., 2011). In contrast, other structures such as the 
hippocampus, remain relatively preserved until almost immediately prior to disease 
onset but then decline rapidly in manifest disease. In addition, the loss of volume in 
the accumbens nucleus, putamen, pallidum and hippocampus was found to impact 
significantly upon clinical measures such as the UHDRS total motor score and total 
functional capacity suggesting a direct relationship between degree of atrophy and 
clinical outcome, which may therefore make them useful as very early markers of 
disease progression.  
 
In this regard, Herben-Dekker and colleagues have demonstrated that glucose 
metabolism in the putamen, as measured by 18-fluorodesoxyglucose (FDG)-PET, was 
lower in a group of pre-manifest HD gene carrier compared to controls (Herben-
Dekker et al., 2014). In this study, participants were grouped according to their 
proximity to disease onset, based upon the outcome of a neurological examination 10 
years after their baseline scan. Those participants identified as being “close” to onset 
(e.g. within 10 years of a diagnosis) all had low-average or abnormal putaminal 
metabolism at a 2 year follow-up scan whereas the far group all had normal 
metabolism in this structure.    
 
This data would appear to suggest that the putamen may be a promising biomarker by 
which to identify PMCG’s at immediate risk of receiving a clinical diagnosis 
although, before this can be fully established longitudinal analysis of changes in the 
putamen is needed in a larger cohort of patients. 
 
 
Lifestyle factors  
The age at which at risk individuals present with overt signs of HD is hugely variable. 
While CAG repeat length can account for between 50%-69% of this variance, the 
other factors behind this variability remain unexplained. Other genetic factors are 
likely to contribute to this relationship as are environmental influences. Researchers 
from the University of Iowa studied the role of substance abuse on age of onset in 136 
HD patients who presented at the University of Iowa Huntington’s disease Society of 
America (HDSA) Centre of Excellence outpatients clinic between 1997 and 2009 
(Byars et al., 2012). They collected information on current and previous drug, alcohol 
and tobacco abuse by participants and accompanying family members as part of the 
Unified Huntington’s Disease Rating Scale (UHDRS) assessment. Where possible 
this information was verified using the patient’s medical records. Participants with a 
history of drug or alcohol abuse were found to have a significantly earlier age of onset 
compared to those who did not. A similar trend was observed for tobacco abuse 
although this failed to reach significance. This effect was predominantly seen in 
women where the presence of at least one substance abuse factor, regardless of type, 
was associated with a significantly younger age of onset. Of course it is not clear 
whether this “abuse” brings out the disease or is an early feature of the condition.  
 
However, the authors do acknowledge several short comings of this study including 
the retrospective data collection and the lack of a formal diagnosis of “abuse”; relying 
instead upon the opinion of the participant and/or family member. In addition, 
information about the duration or extend of abuse was not available to the study team. 
Therefore, it is difficult to evaluate whether these findings are reflective of abuse or 
just periods of increased and/or excessive use. Without this additional information the 
data from this study cannot be used to predict patients who are at increased risk of 
phenoconverting early as it is not possible to establish whether there is a linear 
relationship between these two factors (i.e. as the extent of abuse increases the age of 
onset decreases) or if it is truly categorical as suggested in this article (i.e. abuse 
equals earlier onset, no abuse equals later onset).       
 
Other studies have reported that environmental factors such as increased caffeine 
intake (Simonin et al., 2013) and more time spent in education (Lopez-Sendon et al., 
2011) are also associated with an earlier age of onset. Despite this, the question 
whether early behaviour can impact upon the profile of disease experienced in later 
life is an interesting one and warrants further investigation.  
 
2. Mapping disease progression: 
Cognition 
Executive processes are profoundly affected as a result of the disease process in HD, 
with deficits resembling those seen in patients with lesions to the frontal lobes. This 
pattern of impairment is believed to be a direct result of loss of functional integrity in 
the frontostriatal networks. Abnormalities in manifest disease has been found on a 
range of different tasks including measures of attention (Lawrence et al., 1998), 
planning (Watkins et al., 2000, Papp et al., 2013) cognitive inflexibility (Lawrence et 
al., 1999) and working memory (Pirogovsky et al., 2009, Stout et al., 2011, Dumas et 
al., 2013b). Hart and colleagues (Hart et al., 2012) looked at electrical brain activity in 
relation to high-order cognitive functioning in HD using a measure of attention 
control in combination with EEG. Abnormalities in event-related brain potentials 
(ERP’s) were found in mild HD, but not pre-manifest gene carriers, on a simple 
sustained attention to response test (SART). Specifically, patients with mild HD made 
more Go-errors (failing to respond to stimuli that they should respond to) when 
compared to both pre-manifest HD and controls with most Go-errors being made 
directly following a no-Go error. Contrary to previous literature, there was no 
difference between groups on no-Go error rates. Response times for trials 
immediately surrounding an error were suggestive of a deficit in attention control in 
participants with mild HD with a drop in reaction time (RT) immediately prior to the 
error. HD patients also found it difficult to recover from their errors, taking several 
trials to return to pre-error levels of responding, although this may equally reflect a 
difficulty in switching between Go and no-GO trials. Longer P300 latencies, 
indicating a lower speed of attentional processing, on both Go and no-Go trials is 
supportive of a disturbance in attentional control in patients with mild HD. 
Furthermore, a second, pilot study from the same research group identified an 
increase RT longitudinally over 3 years in manifest patients with greater effects seen 
in trials preceding a correct no-Go trial which was replicated in pre-manifest HD in 
the absence of any cross-sectional differences (Hart et al., 2013).  The relative 
simplicity of this task makes it an ideal candidate as an outcome measure for future 
trials of cognitive enhancing compounds in HD.  
 
Learning and memory deficits have been found in both early and pre-manifest HD 
with abnormalities detected more than a decade from disease onset (Solomon et al., 
2007). However, the neuropathological origin of these early cognitive changes is 
currently poorly understood. While the characteristic loss of striatal integrity seen in 
HD is believed to play a role, the hippocampus is known to be a key brain region 
involved in the formation of new memories (Scoville and Milner, 1957). Elevated 
cortisol levels have been associated with both poorer learning and memory 
performance (Csernansky et al., 2006) and damage to the hippocampus (Sapolsky, 
2000) and while it has been reported in many neurodegenerative and neuropsychiatric 
disorders it has never been formally assessed in HD. 
 
Shirbin and colleagues however, looked at the relationship between elevated cortisol 
levels and learning and memory in HD (Shirbin et al., 2012). The release of cortisol in 
response to psychological and physical stressors is mediated by activity in the 
hypothalamic-pituitary-adrenal (HPA) axis; this neuroendocrinological system has 
been shown to be abnormal in HD and may have value as a possible biomarker of 
disease progression (Petersen and Bjorkqvist, 2006). 
 
In this study, higher evening cortisol levels were associated with a worsening 
impairment in learning and memory performance assessed by the California Verbal 
Learning Task – second version (CVLT-II) in patients with early HD, and those with 
a higher UHDRS total motor score. It was noted that the relationship was more robust 
when the UHDRS was used as a continuous variable compared to the group based 
anlysis (pre-HD Vs early-HD). No relationship was found between recognition 
memory and cortisol levels. The authors interpret their results as evidence of a link 
between dysregulation of cortisol concentration levels and decline in learning and 
memory performance in HD.  
 
The results of this study are principally descriptive and not able to identify causality. 
While they imply a relationship between levels of cortisol concentration and cognitive 
performance it is unclear whether this is mediated by other factors such as 
disturbances in the sleep-wake cycle which has also been shown to be affected in HD 
(Goodman et al., 2011).  Furthermore, the sample size was small, especially when the 
cohort was dichotomised based upon clinical diagnosis (pre-HD Vs early-HD), which 
ultimately reduces the statistical power of the study to detect a relationship.  
 
One of the challenges in mapping the natural history of the cognition changes 
experienced by HD patients is that there are few neuropsychological tasks that are 
relevant at all stages of the disease. Most will result in either ceiling effects when used 
with pre-manifest participants or floor effects when testing advanced patients. Begeti 
et al (Begeti et al., 2013) assessed performance on the Addenbrooke’s Cognitive 
Exam-Revised (ACE-R) as measure of global cognitive performance in a large cohort 
of HD participants ranging from pre-manifest gene carriers to patients with advanced 
disease. The ACE-R was chosen because it is freely available, relatively quick and 
easy to administer without the need for dedicated training. In addition it encompasses 
the Mini Mental State Exam (MMSE) which has been used traditionally to measure 
global cognition but contains additional subsections, particularly in the domain of 
executive function, making it more sensitive in HD. 
 
It was shown that the pattern of impairment identified by the ACE-R changed as the 
disease progressed. In the pre-manifest stage, impairments were found to be selective 
with deficits on phonemic, but not semantic fluency only, although performance did 
not correlate with estimated time to disease onset. By early disease however, patients 
demonstrated deficits on the majority of subdomains with preservation of only the 
attention and language sections. Despite this, a distinct pattern of impairment can be 
seen in both moderate and advanced disease making the ACE-R a practical and 
meaningful way of assessing cognition across the entire disease course. However, it 
should be noted that while this study included follow-up data for a small sub-
population of patients, over a relatively short period, further work is needed to 
establish whether these cross-sectional findings can be replicated through longitudinal 
follow-up of large cohorts of patients.   
 
 
Automatic Nervous System 
Although often under reported, dysfunction of the autonomic nervous system (ANS) 
can be a feature of HD, presenting clinically as gastrointestinal, urinary, 
cardiovascular and sexual problems (Aziz et al., 2010). While there is evidence of 
subtle ANS dysfunction in the pre-manifest stage of disease (Aziz et al., 2010, Kobal 
et al., 2010, Andrich et al., 2002) the neuropathological basis of these abnormalities is 
unclear.   
 
Melik and colleagues (Melik et al., 2012) used a novel task which was believed to be 
sensitive to very subtle differences in ANS function. The microcirculatory response to 
local cooling as a sensor stressor in pre-manifest and early stage HD participants was 
examined along with cardiovascular autonomic testing.  
 
In general, the HD groups as a whole had a higher blood pressure and heart rate than 
controls, however, their response to cooling was less pronounced. The normal 
physiological response to an acute stressor such as local cooling is decreased skin 
blood flow, increased blood pressure and a fall in heart rate (Johnson and Kellogg, 
2010, Minson, 2010). In this study, pre-manifest HD participants exhibited an 
exaggerated microcirculatory response to cooling compared to controls.   
 
The profile of heart rate variability differed between the two HD groups with manifest 
HD participants exhibiting lower low frequency and greater high frequency variability 
than both the pre-manifest group and controls. One possible explanation for this is 
that the variability in heart rate occurs as a result of differences in the emotional state 
of the participants. For example, it may reflect a lower level of anxiety in response to 
the stressor in the manifest HD patients compared to the other groups although 
unfortunately this was not assessed during the study.  
 
In a further study the sensory stressor was replaced by a cognitive stressor (mental 
arithmetic) (Kobal et al., 2014). In this scenario the microcirculatory response to the 
stressor was equivalent between the pre-manifest group and controls, however the 
magnitude of the effect seen in manifest patients was attenuated. Relative laser 
Doppler flux (laser Doppler flux during mental arithmetic expressed as a percentage 
of laser Doppler flux resting rates) increased with advancing motor disease suggesting 
that the cognitive stressors produced less of a cutaneous microvascular response as the 
disease progresses. Furthermore, the heart rate of both HD groups increased less than 
controls during the mental arithmetic task while the increase in blood pressure was 
equivalent between all three groups.  
 
Together, these studies suggest that there are problems in the ANS in HD although, 
how these abnormalities evolve across the duration of the disease and how they relate 
to central HD pathology is still somewhat unclear. Therefore, further work is needed 
to clarify the situation. 
 
Quality of life 
As disease advances patients with HD often struggle to complete self-report 
assessments due to both physical difficulties and a lack of insight into their problems. 
In those situations the opinion of a proxy is often sought to provide information on 
subjective measures such as the patient’s thoughts, beliefs and quality of life. 
Researchers from the University of Reading compared the responses given by 105 
people living with HD to the scores given by their proxy on an HD specific measure 
of health related quality of life to assess inter-rater reliability (Hocaoglu et al., 2012). 
Typically there was good patient-proxy agreement especially for those patients in the 
early and late stages of the disease with less patient-proxy agreement seen when the 
patients were in the middle stages of the disease. When there was patient-proxy 
disagreement the more subjective subscales such as the Specific Hopes and Worries 
Subscale were generally scored more optimistically by proxy’s than by patients; the 
reverse of which is true for both the Specific Cognitive and Specific Physical and 
Functional Scales. It was noted however, that proxies’ ratings of psychosocial aspects 
of quality of life such as on the Specific Hopes and Worries, Specific  Mood State and 
Specific Self and Vitality scales, is influenced by the patients psychological state. 
This study provides evidence that the proxy version of the HDQoL is a useful scale 
that can be used both in combination with, or as an alternative to the self-report 
version.     
 
Conclusions 
The broad scope of the research reviewed here demonstrates the range of different 
approaches that are being taken to prepare for future therapeutic trials in HD; not just 
those which are targeted at delaying the onset and/or slowing down the progression of 
the disease but also extensive work into measure that can also be used in manifest 
disease. To assist with this, extensive work has gone into better defining the clinical 
phenotype of HD, to creating new assessment tools to capture the complexity of the 
symptoms experienced by patients suffering from HD and to better understand factors 
which influence and mark the onset and progression of the disease. Hopefully, this 
work will soon be used to take novel therapies from the lab into the clinic. 
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